Advertisement

AAPS PharmSciTech

, 20:91 | Cite as

Matrix Tablets for Controlled Release of Drugs Incorporated Using Capillary Absorption

  • Uroš MaverEmail author
  • Marko Milojević
  • Jan Štos
  • Samo Adrenšek
  • Odon PlaninšekEmail author
Research Article
  • 45 Downloads

Abstract

Cost and time effectiveness make direct tableting still the favored method for tablet production. Among its most noticeable limitations in application is the non-uniformity (and/or inhomogeneities) in the contents of the resulting tablets, possibly leading to inconsistencies in required tablet properties. The efficiency of direct tableting is mostly affected by surface properties of the components to be tableted, which govern the final tablet mechanical and chemical properties and can influence the liquid capillary rise that the tablets exhibit after ingestion. By using capillary rise as a driving force, we developed a simple, yet powerful procedure for filling blank tablets with a repeatable drug amount. Blank tablets were prepared by direct compression of the excipient and filled with an organic solution of hydrochlorothiazide. Tablets were characterized regarding their structure and morphology, while their applicability was monitored using in vitro drug release studies. By utilizing the mentioned filling of blank tablets, we were able to incorporate the desired dose of the drug inside while maintaining the tablets initial mechanical properties. Moreover, most of the drug was incorporated in the tablet pores and the rest was homogeneously distributed over the tablet surface in the form of small particles, by which we also eliminated content non-uniformity (homogenous drug distribution through the tablet). To sum up, we not only developed a cheap, simple, and reproducible variation of direct tableting, but were also able to eliminate some of its biggest disadvantages (e.g., segregation of components, leading to inhomogeneities in contents, and incompatibility between different base ingredients due to their different surface properties). All mentioned make the proposed approach highly interesting for future use, especially in potential therapy individualization.

KEY WORDS

matrix tablets liquid dispensing technology direct tableting hydrochlorothiazide PROSOLV 

Notes

Acknowledgements

The authors would like to acknowledge the financial support for this study received from the Slovenian Research Agency (grant number: P3-0036 and through the Young Researcher Programme).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Sam A, Fokkens J. The drug delivery system: adding therapeutic and economic value to pharmacotherapy, Part II. Pharm Tech Europe. 1997;9:58–67.Google Scholar
  2. 2.
    Jain KK. Drug delivery systems-an overview. Methods Mol Biol. 2008;437:1–50.CrossRefGoogle Scholar
  3. 3.
    Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat Drug Deliv Formul. 2009;3(2):162–73.CrossRefGoogle Scholar
  4. 4.
    Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts: BI. 2012;2(4):175–87.PubMedGoogle Scholar
  5. 5.
    Armstrong NA. Tablet manufacture by Direct Compression. Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition: CRC Press; 2013. p. 3539–49.Google Scholar
  6. 6.
    Li Z, Zhao L, Lin X, Shen L, Feng Y. Direct compaction: an update of materials, trouble-shooting, and application. Int J Pharm. 2017;529(1–2):543–56.CrossRefGoogle Scholar
  7. 7.
    Mangal S, Meiser F, Morton D, Larson I. Particle engineering of excipients for direct compression: understanding the role of material properties. Curr Pharm Design. 2015;21(40):5877–89.CrossRefGoogle Scholar
  8. 8.
    Li Z, Lin X, Shen L, Hong Y, Feng Y. Composite particles based on particle engineering for direct compaction. Int J Pharm. 2017;519(1–2):272–86.CrossRefGoogle Scholar
  9. 9.
    Bolhuis GK, Anthony Armstrong N. Excipients for direct compaction—an update. Pharm Dev Technol. 2006;11(1):111–24.  https://doi.org/10.1080/10837450500464255.CrossRefPubMedGoogle Scholar
  10. 10.
    Hlinak AJ, Kuriyan K, Morris KR, Reklaitis GV, Basu PK. Understanding critical material properties for solid dosage form design. J Pharm Innov. 2006;1(1):12–7.CrossRefGoogle Scholar
  11. 11.
    Sander C, Holm P. Porous magnesium aluminometasilicate tablets as carrier of a cyclosporine self-emulsifying formulation. AAPS PharmSciTech. 2009;10(4):1388–95.  https://doi.org/10.1208/s12249-009-9340-0. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ruhland T, Nielsen SD, Holm P, Christensen CH. Nanoporous magnesium aluminometasilicate tablets for precise, controlled, and continuous dosing of chemical reagents and catalysts: applications in parallel solution-phase synthesis. J Comb Chem. 2007;9(2):301–5.CrossRefGoogle Scholar
  13. 13.
    Cosijns A, Vervaet C, Luyten J, Mullens S, Siepmann F, Van Hoorebeke L, et al. Porous hydroxyapatite tablets as carriers for low-dosed drugs. Eur J Pharm Biopharm. 2007;67(2):498–506.CrossRefGoogle Scholar
  14. 14.
    Planinsek O. Porous tablets for subsequent filling with active pharmaceutical ingredient. Google Patents; 2007.Google Scholar
  15. 15.
    Holm P, Holm JE, Ruhland T, Dalsgaard S. Porous tablets as carriers for liquid formulations. Google Patents; 2005.Google Scholar
  16. 16.
    Lee F-Y, Lee F-C. Chargeable pharmaceutical tablets. Google Patents; 2002.Google Scholar
  17. 17.
    Clarke A, Doughty D. Development of liquid dispensing technology for the manufacture of low dose drug products. In: Kleinebudde P, Khinast J, Rantanen J, editors. Continuous Manufacturing of Pharmaceuticals: Wiley; 2017.Google Scholar
  18. 18.
    Awad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW. Reshaping drug development using 3D printing. Drug Discov Today. 2018;23(8):1547–55.  https://doi.org/10.1016/j.drudis.2018.05.025.CrossRefPubMedGoogle Scholar
  19. 19.
    Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018;39(5):440–51.  https://doi.org/10.1016/j.tips.2018.02.006.CrossRefPubMedGoogle Scholar
  20. 20.
    Khaled SA, Alexander MR, Wildman RD, Wallace MJ, Sharpe S, Yoo J, et al. 3D extrusion printing of high drug loading immediate release paracetamol tablets. Int J Pharm. 2018;538(1–2):223–30.  https://doi.org/10.1016/j.ijpharm.2018.01.024.CrossRefPubMedGoogle Scholar
  21. 21.
    Wickström H, Hilgert E, Nyman J, Desai D, Şen Karaman D, de Beer T, et al. Inkjet printing of drug-loaded mesoporous silica nanoparticles—a platform for drug development. Molecules. 2017;22(11):2020.CrossRefGoogle Scholar
  22. 22.
    Sandler N, Ihalainen P. Perspectives of printing technologies in continuous drug manufacturing. In: Kleinebudde P, Khinast J, Rantanen J, editors. Continuous Manufacturing of Pharmaceuticals: Wiley; 2017.Google Scholar
  23. 23.
    Pharmacopeia U. United States Pharmacopeia and National Formulary (USP 37–NF 32). Vol Section. 2014;2:35–117.Google Scholar
  24. 24.
    Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–33.CrossRefGoogle Scholar
  25. 25.
    Matos APS, Costa JS, Boniatti J, Seiceira RC, Pitaluga A, Oliveira DL, et al. Compatibility study between diazepam and tablet excipients. J Therm Anal Calorim. 2017;127(2):1675–82.  https://doi.org/10.1007/s10973-016-5350-9.CrossRefGoogle Scholar
  26. 26.
    Collier JW, Shah RB, Gupta A, Sayeed V, Habib MJ, Khan MA. Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate. AAPS PharmSciTech. 2010;11(2):818–25.  https://doi.org/10.1208/s12249-010-9434-8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Chadha R, Bhandari S. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal. 2014;87:82–97.  https://doi.org/10.1016/j.jpba.2013.06.016.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim BH, Kim JK. Pharmaceutical studies on the polymorphism of hydrochlorothiazide. Arch Pharm Res. 1984;7(1):47–52.  https://doi.org/10.1007/bf02856921.CrossRefGoogle Scholar
  29. 29.
    Godec A, Maver U, Bele M, Planinsek O, Srcic S, Gaberscek M, et al. Vitrification from solution in restricted space: formation and stabilization of amorphous nifedipine in a nanoporous silica xerogel carrier. Int J Pharm. 2007;343(1–2):131–40.  https://doi.org/10.1016/j.ijpharm.2007.05.022.CrossRefPubMedGoogle Scholar
  30. 30.
    Maver U, Godec A, Bele M, Planinsek O, Gaberscek M, Srcic S, et al. Novel hybrid silica xerogels for stabilization and controlled release of drug. Int J Pharm. 2007;330(1–2):164–74.  https://doi.org/10.1016/j.ijpharm.2006.09.024.CrossRefPubMedGoogle Scholar
  31. 31.
    Maver U, Žnidaršič A, Saboti D, Srčič S, Gaberšček M, Godec A, et al. The relation between the interfacial contact and SiO2 coating efficiency and properties in the case of two clarithromycin polymorphs. Colloids Surf A Physicochem Eng Asp. 2010;371(1–3):119–25.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Faculty of Medicine, Institute of Biomedical SciencesUniversity of MariborMariborSlovenia
  2. 2.Faculty of Medicine, Department of PharmacologyUniversity of MariborMariborSlovenia
  3. 3.Center for Validation Technologies and AnalyticsNational Institute of ChemistryLjubljanaSlovenia
  4. 4.Faculty of PharmacyUniversity of LjubljanaLjubljanaSlovenia

Personalised recommendations